Lab Discovery Chokes Aggressive Cancer Tumors

Scientist examining samples under a microscope in a laboratory

UCLA researchers have found a hidden flaw inside some of the deadliest cancers known to medicine — and it may be the key to stopping them.

Story Snapshot

Cancers that lose a gene called RB become dangerously dependent on a protein called E2F3 to survive — and that dependency can be exploited.
In lab studies, blocking E2F3 stopped tumor cells from dividing, prevented them from clustering, and caused some to die outright.
Researchers found a drug pathway — blocking an enzyme called DHODH — that reduces E2F3 levels and slows tumor growth.
This strategy, known as synthetic lethality, targets only cancer cells, potentially sparing healthy tissue from damage.

The Gene That Keeps Cancer in Check — Until It Disappears

Think of the RB gene as a brake pedal for cell growth. When it works, cells divide in an orderly way. When cancer destroys it, cells multiply without control. RB loss is not rare — it happens in nearly all small cell cancers, a group that includes some of the most aggressive tumors in the lung, prostate, and other tissues. These cancers are notoriously hard to treat and tend to resist standard therapies. That is exactly why the UCLA discovery matters so much.

When RB disappears, cancer cells do not just grow faster — they grow desperate. They lean hard on other proteins to keep themselves alive. UCLA researchers identified E2F3 as the protein these cells cannot live without. Remove it, and the cancer stalls. This concept — using one weakness to trigger another fatal one — is called synthetic lethality. Scientists have used this idea before in other cancers, but applying it to RB-deficient small cell tumors is a significant step forward.

What the Lab Experiments Actually Showed

The research team used a genome-wide CRISPR screen — a powerful tool that tests thousands of genes at once — to find which ones RB-deficient cancer cells could not survive without. E2F3 kept showing up as the critical target across small cell cancer models from the prostate, lung, and adnexa. When researchers reduced E2F3 levels, cells stopped dividing, could not form the clusters that tumors need to grow, and in some cases died completely.

The team also found a practical way to reduce E2F3 without directly attacking the protein itself. They blocked an enzyme called DHODH, which cancer cells use to build the DNA building blocks they need to keep dividing. Cutting off that supply lowered E2F3 levels and slowed tumor growth in both cell cultures and animal models. That is a meaningful result because DHODH is a known drug target, meaning existing compounds already exist that can block it.

Why This Fits a Bigger Pattern in Cancer Research

This is not the first time scientists have turned RB loss into a target. Researchers at MD Anderson Cancer Center found that RB-deficient breast cancer cells become vulnerable to blocking two DNA repair proteins called ATR and PKMYT1. Other teams have shown that RB loss makes tumors sensitive to PARP inhibitors and drugs that disrupt RNA splicing. The UCLA finding is the latest in a decade-long effort to flip the script on RB loss — turning a cancer’s greatest strength into its greatest weakness.

The Honest Limits of What We Know So Far

None of this has been tested in human patients yet. Every result so far comes from lab cultures and animal models. That is standard for early-stage cancer research, but it is an important distinction. Roughly 85% of preclinical cancer breakthroughs never make it to approved treatments. The exact molecular steps between blocking DHODH and reducing E2F3 are also not fully mapped. And researchers have only tested three cancer tissue types, leaving open the question of whether E2F3 dependency holds in other small cell cancers like esophageal or cervical tumors.

A UCLA study has identified a hidden Achilles' heel in aggressive small cell cancers that have resisted new treatments for decades. Scientists found that tumors lacking the RB gene become critically dependent on the protein E2F3 for survival. Blocking E2F3https://t.co/Ntjm9ykfZ7

— Michael W. Deem (@Michael_W_Deem) July 5, 2026

There is also the question of safety. DHODH inhibition cuts off pyrimidine synthesis — a process that healthy cells also rely on. Whether that causes meaningful harm to normal tissue in humans is not yet known. These are not reasons to dismiss the discovery. They are the honest next questions that clinical trials must answer. The good news is that DHODH inhibitors already exist and are being studied at UCLA in other cancer contexts, which could speed up the path to human trials for this specific application.

What Comes Next and Why It Matters

Small cell cancers are brutal. They spread fast, resist treatment quickly, and leave patients with few options. Any legitimate new angle of attack deserves serious attention and serious funding. The UCLA team has published their findings in the Proceedings of the National Academy of Sciences, one of the most respected journals in science. That is not a press release claim — that is peer-reviewed work. The next step is a Phase I clinical trial to test safety in humans, and that work cannot come fast enough for the patients who need it.